1H16 results in line; positive NIM migration offset by higher credit costs 1H 2016 Results Presentation Key Takeaway. Continues To Gain Market Share. Increased concerns about execution ability; downgrade to UW 汇富快讯 Please the eye and plague the heart Downgrade on hospitals revamping Q2 Recurring Net Profit Resumed YoY Growth; Reiterate BUY 晨早快讯 Transition taking place, raise PT to HK$5.5 1H16–Key takeaways from analyst meeting

每日晨讯 收购诺华产品布局骨科领域，产品线逐步丰富 Earnings Growth Resumed in 1H16; Reiterate BUY 1H16 results in line; positive NIM migration offset by higher credit costs 1H 2016 Results Presentation Key Takeaway. Continues To Gain Market Share. 汇富快讯 Please the eye and plague the heart On-track overseas expansion to ease pressure in China market Downgrade on hospitals revamping Q2 Recurring Net Profit Resumed YoY Growth; Reiterate BUY